Stem is trading at $2.70, down 5.80% versus the regular-session close in after-hours trading; no fresh company announcement explaining the October 27 decline was identified.
- Stem announced a strategic-alternatives review on October 26, including a possible sale or merger; it gave no timetable and no assurance of a transaction.
- The review is relevant background, not a confirmed cause of the drop. The provided market context was positive and does not explain Stem’s decline.